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Abstract: Glycosaminoglycans (GAGs) are a class of biomolecules expressed virtually on all
mammalian cells and usually covalently attached to proteins, forming proteoglycans. They are
present not only on the cell surface, but also in the intracellular milieu and extracellular matrix.
GAGs interact with multiple ligands, both soluble and insoluble, and modulate an important role
in various physiological and pathological processes including cancer, bacterial and viral infections,
inflammation, Alzheimer’s disease, and many more. Considering their involvement in multiple
diseases, their use in the development of drugs has been of significant interest in both academia and
industry. Many GAG-based drugs are being developed with encouraging results in animal models
and clinical trials, showcasing their potential for development as therapeutics. In this review, the role
GAGs play in both the development and inhibition of cancer and inflammation is presented. Further,
advancements in the development of GAGs and their mimetics as anti-cancer and anti-inflammatory
agents are discussed.
Keywords: glycosaminoglycans; mimetics; heparin; heparan sulfate; chondroitin sulfate; dermatan
sulfate; hyaluronan; keratan sulfate; anti-cancer; anti-inflammation

1. Introduction
Glycosaminoglycans (GAGs) are linear polysaccharides whose disaccharide building blocks consist
of an amino sugar (d-glucosamine that is N-acetylated, or N-sulfated, or N-acetyl-d-galactosamine) and
either uronic acid (d-glucuronic acid or L-iduronic acid) or galactose. GAGs are sometimes referred
to as mucopolysaccharides as they were originally characterized in mucus membranes and mucosal
exudates. GAGs are differentiated from one another based on the type of monomeric unit, linkages
between each monomeric unit, the position of sulfate groups, and the degree of sulfation. Based on
these features, GAGs can be broadly classified into four different classes (Figure 1): chondroitin
sulfate/dermatan sulfate (CS/DS), heparin/heparan sulfate (HS), hyaluronan (HA), and keratan sulfate
(KS) [1].
GAGs are highly charged owing to negatively-charged carboxylic acid units present on the
uronic acid residues and sulfate groups present on most of the units. HA is the only GAG that is
not sulfated and, hence, is the least negatively-charged GAG, while heparin is the most negatively
charged. Although each of these GAGs has a predominant disaccharide component as mentioned
above, as a result of the non-template-driven biosynthetic pathway by which they are produced,
these disaccharides can be modified at multiple positions by sulfation, acetylation, and/or epimerization,
creating a tremendous amount of heterogeneity in any particular class of GAGs [2].
GAGs are involved in a myriad of biological functions. Most of the biological interactions
mediated by proteoglycans are believed to be primarily because of the GAG chains present on
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Table 1. Different classes of GAG-binding proteins and their biological activities.
Table 1. Different classes of GAG-binding proteins and their biological activities.
Class of Binding Proteins
Class of Binding Proteins
Enzymes
Enzymes
Enzyme inhibitors
Enzyme inhibitors

Physiological Function
Example
Physiological Function
Example
Coagulation
Factor Xa [4]
Coagulation
Factor Xa [4]
Coagulation, inflammation
Antithrombin III [4]
Coagulation, inflammation
Antithrombin III [4]
Cell adhesion,
Platelet/endothelial cell adhesion
Cell adhesion proteins
Cell adhesion, inflammation,
Platelet/endothelial cell adhesion
inflammation,
metastasis
molecule-1 [5]
Cell adhesion proteins
metastasis
molecule-1 [5]
Extracellular matrix (ECM)
Cell adhesion, matrix organization
Annexin V [6]
Extracellular proteins
matrix (ECM)
Cell adhesion, matrix organization
Annexin V [6]
proteins
Growth factors
Mitogenesis, cell migration
Fibroblast growth factor [7,8]
Growth factors
Mitogenesis,Chemotaxis,
cell migration
Fibroblast growth factor [7,8]
Chemokines
IL-8 [9]
Chemokines
Chemotaxis,signaling
signalinginflammation
inflammation
IL-8 [9]
Morphogens
Morphogens
Lipid-binding proteins
Lipid-binding proteins
Pathogen surface proteins
Pathogen surface proteins
Viral proteins
Viral proteins

Cell specification,
Cell specification,
tissuetissue
differentiation, development
differentiation, development
Lipid metabolism,
Lipid metabolism, cell membrane
cell membrane functions
functions
Pathogen infections
Pathogen infections
Viral infections
Viral infections

BMP-2[10]
[10]
BMP-2
Lipoprotein lipase [11]
Lipoprotein lipase [11]
Circumsporozoite [12]
Circumsporozoite [12]
Glycoprotein D [13]
Glycoprotein D [13]

Since GAGs are involved in a plethora of biological activities, their use in the development of
drugs has been of long interest in the pharmaceutical industry. Heparin, the first GAG-based drug,
is used as an anticoagulant for the treatment of thrombosis, thrombophlebitis, and embolism [14].
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Since GAGs are involved in a plethora of biological activities, their use in the development of
drugs has been of long interest in the pharmaceutical industry. Heparin, the first GAG-based drug,
is used as an anticoagulant for the treatment of thrombosis, thrombophlebitis, and embolism [14].
The therapeutic potential of GAGs and their mimetics for the treatment of many other diseased states,
including cancer, inflammation, infection, wound healing, lung diseases, Alzheimer’s disease, etc.,
are being actively studied [15]. In this review, however, only the role and therapeutic application of
GAGs and GAG mimetics in cancer and inflammation will be discussed.
2. Role of GAGs in Cancer
Interaction of GAGs with growth factors, growth factor receptors, and cytokines are implicated in
cancer growth, progression, and metastasis [16]. GAGs are found to be involved in multiple signaling
cascades required for angiogenesis, cancer invasion, and metastasis. Interestingly, some GAGs have
also been shown to play a role in the inhibition of tumor progression. Understanding the type of
interaction and the role these GAGs play in multiple cancer types has led to the development of various
therapeutic approaches and novel drugs to treat cancer [17].
2.1. Heparin/HS in Cancer
Heparan sulfate proteoglycans (HSPGs) through their core proteins and GAG side chains modulate
multiple functions of tumor cells and are involved in tumor growth, invasion, and metastasis [18,19].
HS has been shown to promote cell-cell and cell-ECM adhesion, inhibiting invasion and metastasis,
and a decrease in the levels of HS, as seen in some cancers, resulted in the malignant cells being more
invasive [7,20]. While the levels of HS are decreased in some cancers, others display modifications in their
sulfation pattern, which are shown to be responsible for cancer progression. For example, highly-sulfated
HS is shown to trigger cell proliferation through fibroblast growth factor 2 (FGF2) signaling, in melanoma
cells [8]. Additionally, in the case of colon cancer, these modifications were also found to be highly
dependent on the anatomical location (right-side vs. left-side) and the metastatic/non-metastatic nature
of the tumor. Surprisingly, metastatic right-sided colorectal cancers were found to exhibit fewer
changes to the structure of HS when compared to the non-metastatic tumors [21,22]. HS also plays
a crucial role in epithelial to mesenchymal transition (EMT) due to its ability to bind to growth factors
present in the tumor microenvironment [23].
HSPGs, such as syndecan-1 and syndecan-4, have been associated with breast cancer progression
by the formation of complexes with FGF2 and fibroblast growth factor receptor 1 (FGFR-1) [24]. It was
also shown that syndecan-4 expression promotes tumor adhesion and migration in melanoma cells [25].
Another class of HSPGs, glypican-3, is found to play a variable role in tumors. For example, it is shown
to promote tumor growth in hepatocellular carcinoma and melanoma by stimulating Wnt signaling [26],
whereas it inhibited tumor growth by inducing apoptosis in breast and ovarian cancers [18]. However,
glycosylphosphatidylinositol-anchored glypicans, when overexpressed, are associated with tumor
growth in hepatocellular carcinoma and melanoma.
Over-expression of heparanase (HPSE), an enzyme that cleaves HS chains of HSPGs at β-1,4
positions, has been shown to be involved in mechanisms promoting tumor growth, angiogenesis,
and metastasis [27–29]. HPSE also enhances the phosphorylation of Src and epidermal growth factor
receptor (EGFR), activating STAT3, which is associated with head and neck cancer progression [30].
It further stimulates an increase in the expression of both hepatocyte growth factor and syndecan-1,
resulting in an aggressive phenotype [31]. On the contrary, heparanse-2 inhibits the activity of HPSE,
thereby acting as a tumor suppressor [32].
Downregulation of human sulfatase-1 (SULF1), a heparin-degrading endosulfatase, observed in
breast cancer cells, is shown to increase cell migration and invasion [33]. Human sulfatase-2 (SULF2),
an HS 6-O-endosulfatase, was found to inhibit in vivo tumor growth in human breast cancer xenograft
models [34]. Conversely, in the case of lung cancer, it is shown to promote carcinogenesis [35].
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CS/DS is involved in the regulation of critical cellular processes, such as proliferation, apoptosis,
CS/DS is involved in the regulation of critical cellular processes, such as proliferation, apoptosis,
migration, adhesion, and invasion [36]. The CS/DS side chains of chondroitin sulfate proteoglycans
migration, adhesion, and invasion [36]. The CS/DS side chains of chondroitin sulfate proteoglycans
(CSPGs) participate in various interactions within the ECM, which is of particular importance in
(CSPGs) participate in various interactions within the ECM, which is of particular importance in
malignancy. For example, increased levels of versican, a CSPG, has been correlated with disease
malignancy. For example, increased levels of versican, a CSPG, has been correlated with disease
progression in early-stage breast and prostate cancers [37,38]. Changes to the CS chains of versican
progression in early-stage breast and prostate cancers [37,38]. Changes to the CS chains of versican
with enhanced expression of 6-O-sulfated and non-sulfated disaccharide units was observed in
with enhanced expression of 6-O-sulfated and non-sulfated disaccharide units was observed in a
a malignant phenotype of pancreatic cancer [39]. In the case of melanoma, increased levels of
malignant phenotype of pancreatic cancer [39]. In the case of melanoma, increased levels of
melanoma-associated chondroitin sulfate proteoglycan (MCSP) are observed, which enhances integrin
melanoma-associated chondroitin sulfate proteoglycan (MCSP) are observed, which enhances
function, thereby activating Erk1/2 and stimulating cell growth and motility [40].
integrin function, thereby activating Erk1/2 and stimulating cell growth and motility [40].
Structural alterations to CS chains, especially their sulfation pattern, is associated with cancer
Structural alterations to CS chains, especially their sulfation pattern, is associated with cancer
progression [41]. For example, chondroitin-4,6-disulfate or CS-E (Figure 2), a type of CS, is overexpressed
progression [41]. For example, chondroitin-4,6-disulfate or CS-E (Figure 2), a type of CS, is
in multiple cancer types. High expression of CS-E is correlated with increased binding to vascular
overexpressed in multiple cancer types. High expression of CS-E is correlated with increased binding
endothelial growth factor (VEGF) in ovarian adenocarcinomas [42]. A higher proportion of CS-E was
to vascular endothelial growth factor (VEGF) in ovarian adenocarcinomas [42]. A higher proportion
found in the highly-metastatic LM660H11 lung carcinoma cell line, when compared to the P29 cell line
of CS-E was found in the highly-metastatic LM660H11 lung carcinoma cell line, when compared to
with low metastatic potential, suggesting the role of CS-E in metastasis [43]. It was also shown that
the P29 cell line with low metastatic potential, suggesting the role of CS-E in metastasis [43]. It was
overexpression of CS-E causes colonization of osteosarcoma cells in the liver [44].
also shown that overexpression of CS-E causes colonization of osteosarcoma cells in the liver [44].
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2.3. HA in Cancer
2.3. HA in Cancer
Increased levels of HA are found in multiple types of human cancers, including breast [47], lung [48],
Increased levels of HA are found in multiple types of human cancers, including breast [47],
and ovarian cancer [49]. Growth factors and chemokines present in the tumor microenvironment
lung [48], and ovarian cancer [49]. Growth factors and chemokines present in the tumor
are known to induce HA production [50]. On the other hand, low levels of HA are associated with
microenvironment are known to induce HA production [50]. On the other hand, low levels of HA are
metastatic potential in squamous cell carcinoma [51] and melanoma [52].
associated with metastatic potential in squamous cell carcinoma [51] and melanoma [52].
CD-44, in the presence of high levels of HA, is found to interact with signaling receptors such as
CD-44, in the presence of high levels of HA, is found to interact with signaling receptors such as
EGFR to stimulate downstream pathways involving PI3k/Akt and/or mitogen-activated protein (MAP)
EGFR to stimulate downstream pathways involving PI3k/Akt and/or mitogen-activated protein
kinases promoting chemoresistance and breast cancer progression [53–55]. Moreover, degradation
(MAP) kinases promoting chemoresistance and breast cancer progression [53–55]. Moreover,
of HA to smaller oligosaccharides by hyaluronidases is reported to induce cleaving of CD-44 in the
degradation of HA to smaller oligosaccharides by hyaluronidases is reported to induce cleaving of
tumor microenvironment, leading to tumor progression, as seen in breast, ovarian, glioma, and colon
CD-44 in the tumor microenvironment, leading to tumor progression, as seen in breast, ovarian,
cancers [56,57].
glioma, and colon cancers [56,57].

2.4. GAGs as Anti-Cancer Agents
Several researchers have worked on utilizing the involvement of GAGs in cancer to develop
therapeutics. For example, heparin, in addition to its anticoagulant properties, also possesses
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2.4. GAGs as Anti-Cancer Agents
Several researchers have worked on utilizing the involvement of GAGs in cancer to develop
therapeutics. For example, heparin, in addition to its anticoagulant properties, also possesses anti-cancer
properties [58,59]. However, its anticoagulant property limits its development as an anticancer agent.
Taking this into consideration, non-anticoagulant heparin analogs inhibiting heparanase in vitro and
in vivo have been developed [60–62].
A non-anticoagulant HS, isolated from the bivalve mollusk Nodipecten nodosus, has been
shown to inhibit P-selectin-mediated events such as metastasis of Lewis lung carcinoma cells [63].
Another modified non-anticoagulant heparin, SST0001 or Roneparstat, was developed by Sigma-Tau
Pharmaceuticals as a potent heparanase inhibitor [61]. SST0001 is 100% N-acetylated and 25% glycol
split high-molecular weight heparin, and hence, the microheterogeneity of the original heparin is
retained in it. In preclinical murine models, it showed a significant reduction in tumor volume in
multiple myeloma mice xenograft models and was also recently tested in Phase I clinical trials for
advanced multiple myeloma [61].
M402 or necuparanib is another molecule developed as a non-anticoagulant heparin [60].
It is obtained from depolymerization of low molecular weight heparin followed by oxidation and
borohydride reduction, resulting in a glycol split. It was found to inhibit multiple targets involved
in tumor progression and metastasis, including heparanase, VEGF, FGF2, P-selectin, and stromal
cell-derived factor-1α (SDF-1α). It showed a reduction in tumor metastasis and statistically-significant
survival benefits in preclinical studies [64]. However, the Phase II clinical study in combination with
nab-paclitaxel and gemcitabine for pancreatic cancer was terminated due to an insufficient level of
efficacy in the study population.
Desai and co-workers found that a particular non-anticoagulant hexasaccharide sequence of HS,
called HS06, selectively inhibited cancer-stem-cell (CSC) self-renewal and induced apoptosis in several
colorectal, breast, and pancreatic cell lines [65]. The inhibition of self-renewal was found to be because
of activation of p38α/β mitogen-activated protein kinase (MAPK), which led to inhibition of TCF4
signaling, a critical regulator of CSC self-renewal. Additionally, it was also found that either shorter or
longer saccharide sequences of HS were not able to inhibit CSCs as potently as HS06, portraying the
specificity of GAG–protein interactions.
Sasisekharan and coworkers utilized the differential substrate specificity of heparinase I (Hep I)
and heparinase III (Hep III) to generate different oligosaccharide GAG fragments from the tumor cell
surface [66]. Interestingly, the fragments generated from Hep I promoted tumor growth, whereas Hep
III generated fragments were found to inhibit tumor growth and metastasis. Further analysis showed
that these GAG fragments inhibited tumor growth in vivo in a dose-dependent fashion with >70%
reduction in primary tumor growth at a dose of 10 µg/kg/day in mice models.
Apart from heparin/HS GAGs, CS/DS-based targeting in cancer has also been widely studied.
Fucosylated CS (FucCS), isolated from sea cucumber, was found to inhibit tumor metastasis in vivo by
blocking P- and L-selectin-mediated events [67]. Exogenous CS-A has been shown to be effective in
decreasing monocyte migration, thereby preventing angiogenesis in vitro [68]. Novel molecules called
neoglycans, produced by modifying CS chains with carbodiimide, reduced tumor growth in nude
mice with breast cancer without apparent toxicity to the normal tissue [69]. These studies prove the
potential use of GAGs or modified GAGs as potent anticancer agents.
3. Role of GAGs in Inflammation
Inflammation is a defense mechanism of the body to harmful stimuli. This protective action
primarily involves the recruitment of immune cells from the bloodstream into the site of injury/infection.
Some of the major events during the inflammation process are intimately regulated by GAGs, especially
those coating the surface of endothelial cells and leukocytes [70–75]. At the site of injury/infection,
GAGs are involved in leukocyte rolling along the endothelial surface; regulation of chemokine
migration and activation; and trans-endothelial migration of leukocytes.
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Upon inflammatory trigger, macrophages at the site of infection/injury release cytokines,
which activate endothelial cells, resulting in the display of P-selectins on their surface. P-selectin
glycoprotein ligand-1 (PSGL-1) on leukocytes interact with activated endothelial cells by binding
to P-selectins. The PSGL-1-P-selectin interaction enables leukocytes’ adhesion onto the endothelial
layer [70]. Upon leukocyte adhesion on the endothelial cells, HS on the surface of endothelial cells
binds to L-selectins on leukocyte, leading to leukocyte rolling [71]. Regulation of leukocyte rolling is
the first role of GAGs in inflammation.
Macrophages at the site of infection/injury also release significant amounts of chemokines, in
addition to cytokines. The released chemokines, particularly IL-8 (CXCL-8), bind to GAGs at the
endothelial surface, leading to chemokine transcytosis [72]. After transcytosis across the endothelial
layer, leukocytes are recruited by the interaction of integrin on leukocytes with intercellular adhesion
molecule-1 (ICAM-1) on the endothelial surface. This interaction leads to increased adhesion of
leukocytes onto the endothelium, thereby slowing down the rolling of leukocytes. This triggers
morphological changes required for the migration of leukocytes through the endothelial barrier.
Syndecan, a proteoglycan containing HS chains, plays a major role in this migration process [73].
Heparin is synthesized and stored in certain types of mast cells and is co-released with histamine
upon inflammatory trigger [74]. Released heparin induces the formation of bradykinin and helps in
vascular permeability [75].
GAGs as Anti-Inflammatory Agents
Due to the tremendous role played by GAGs throughout the inflammation process, exogenous
sulfated glycans of various structures can be used to downregulate inflammation processes. Many such
molecules have been tested in in vitro and in vivo models, and some have even reached clinical trials.
Besides its use as an anticoagulant, heparin demonstrated excellent anti-inflammatory properties
in animal models and clinical trials [76]. Heparin has been shown to be useful for the treatment of
bronchial asthma [77], ulcerative colitis [78], and burns [79]. Although these studies showed promising
results, heparin is not approved for use as an anti-inflammatory agent because of the associated
bleeding risk. Several non-anticoagulant heparin mimetics were developed thereafter to maintain its
anti-inflammatory effect [80]. One such example is 2-O,3-O-desulfated heparin (ODSH), which was
shown to reduce airway inflammation by potently inhibiting human neutrophil elastase without
any anticoagulant effects [81]. Another non-anticoagulant heparin isolated from shrimp Litopenaeus
vannamei has significantly reduced the influx of inflammatory cells to the site of injury in acute
inflammation models [82].
Exogenous DS of a specific length is found to inhibit P-selectins in inflammatory mouse models [83].
On the other hand, CS is found to inhibit inflammation in rat astrocytes by preventing NF-κB
activation [84].
KS has been shown to ameliorate the pathological conditions associated with inflammation [85].
For example, exogenously-added KS reduced damage in cartilage explants that were exposed to
interleukin-1α ex vivo. Since cartilage fragments can cause an antigenic response, resulting in an increase
in inflammation and arthritic response, reduced cartilage degradation can be correlated to a reduction
in the severity of arthritis [86]. In addition, when tested in vivo using a murine arthritis model, KS was
found to ameliorate arthritis [86]. Plasma levels of KS have been identified as a potential biomarker
for joint damage in juvenile idiopathic arthritis [87]. In the cornea, KS proteoglycans are found to
bind to chemokine CXCL1 and facilitate its migration into the stroma during inflammation [88].
The addition of low molecular weight KS resulted in the disruption of this KS-CXCL1 complex, leading
to efflux of chemokines and resolution of inflammation [89]. In a study by Taniguchi and coworkers,
a KS disaccharide, [SO3 − -6]Galβ1-4[SO3 − -6]GlcNAc, prevented neutrophil-mediated inflammation
and progression of emphysema in murine models, indicating its potential use for the treatment of
inflammation in chronic obstructive pulmonary disease [90,91].
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These works clearly indicate the potential of using GAGs and related compounds as
anti-inflammatory agents.
4. GAG Mimetics
Although GAGs have tremendous applications as therapeutics, there are many challenges
associated with their structure, halting their success in clinical trials. As previously mentioned,
GAGs are complex heterogeneous molecules with exceptional structural diversity, which not only
differ in their length, but are also modified at multiple positions through sulfation, acetylation,
and epimerization. This inherent heterogeneity involved in the biosynthesis of GAGs leads to
a particular GAG binding to many different proteins, thus compromising selectivity and leading to
side-effects when given as a therapeutic [16,92].
Furthermore, GAGs are usually obtained from animal sources. For example, heparin, one of the
oldest drugs in the clinic, is obtained from porcine intestine, bovine intestine, and bovine lung. Hence,
the quality of heparin obtained depends on the environmental conditions and the diet each animal is
exposed to and results in significant batch-to-batch variation [93]. The heterogeneity of GAGs makes
the complete characterization of every batch of heparin produced nearly impossible, thereby making
quality control a daunting task [94]. In 2008, contamination of heparin with over-sulfated CS resulted
in over 200 deaths and thousands of adverse effects in the United States alone [95].
To address the issues involved in the development of GAGs as therapeutics, multiple strategies
have been developed to mimic GAGs through small molecules called GAG mimetics [92]. GAG mimetics
have numerous advantages over GAGs as therapeutics. They are usually completely synthetic and
homogenous molecules and hence are expected to have increased selectivity and fewer adverse
effects [96]. They are easier to produce at large scales, design computationally, characterize, and quality
control. They also have better pharmacokinetic features than GAGs, making them more ‘drug-like’.
GAG mimetics can be classified into two classes: saccharide-based and non-saccharide-based.
Saccharide-based GAG mimetics, although built on a sugar backbone, are synthetic and not produced
from animal sources. They are less heterogeneous when compared to GAGs. On the other hand,
non-saccharide-based mimetics utilize non-sugar-based scaffolds carrying negative charges through
sulfates, sulfonates, carboxylates, and/or phosphates. They are completely homogenous molecules and
provide numerous advantages over saccharide-based mimetics. Both saccharide and non-saccharide
GAG mimetics have been developed for the treatment of cancer and inflammation, and a few are
currently in clinical trials, while some are marketed in the clinic. Here, I discuss the GAG mimetics that
have shown remarkable potential and made huge advancements in the fields of cancer and inflammation.
4.1. GAG Mimetics as Anti-Cancer Agents
4.1.1. Saccharide-Based GAG Mimetics
Phosphomannopentaose sulfate (PI-88; Figure 3A) is an HS mimetic obtained via sulfation of
the phospho-mannan complex produced from yeast cultures [97]. It is a heterogeneous mixture of
di- to hexa-saccharides, but mostly tetra- (60%) and penta-saccharides (30%). PI-88 potently inhibits
the activity of heparanase, an enzyme that plays a vital role in metastasis and angiogenesis. It was
also found to bind to pro-angiogenic growth factors VEGF, FGF1, and FGF2 by competing with HS.
Although PI-88 also possesses anticoagulant activity, in addition to anticancer activity, it appeared to
be well tolerated in preclinical models and was hence investigated further in clinical trials. It reached
Phase III clinical trials for hepatocellular carcinoma, which was concluded after interim analysis due to
the failure to reach the primary disease-free survival endpoint [98].
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Figure
Chemical structure
structure of
Figure 3.
3. Chemical
of (A)
(A) PI-88
PI-88 and
and (B)
(B) PG545.
PG545.

Several second-generation analogs of PI-88 that are anomerically pure, completely sulfated,
Several second-generation analogs of PI-88 that are anomerically pure, completely sulfated, and
and homogeneous were later developed by Progen Pharmaceuticals Ltd. Among these analogs, PG545
homogeneous were later developed by Progen Pharmaceuticals Ltd. Among these analogs, PG545 or
or pixatimod (Figure 3B) was selected as the lead compound [99]. In addition to being a fully-sulfated,
pixatimod (Figure 3B) was selected as the lead compound [99]. In addition to being a fully-sulfated,
anomerically-pure, homogenous compound, PG545 has a lipid moiety attached at the reducing end,
anomerically-pure, homogenous compound, PG545 has a lipid moiety attached at the reducing end,
which resulted in improved pharmacokinetic properties and reduced anticoagulant activity [100].
which resulted in improved pharmacokinetic properties and reduced anticoagulant activity [100]. It
It also resulted in increased affinity towards heparanase as a result of the lipid moiety’s binding in
also resulted in increased affinity towards heparanase as a result of the lipid moiety’s binding in the
the hydrophobic pocket [101]. It showed potent antitumor and anti-metastatic activity in several
hydrophobic pocket [101]. It showed potent antitumor and anti-metastatic activity in several
preclinical models and is currently in Phase I clinical trials for advanced solid tumors and metastatic
preclinical models and is currently in Phase I clinical trials for advanced solid tumors and metastatic
pancreatic cancer.
pancreatic cancer.
Dollé and coworkers synthesized an octasaccharide heparin mimetic that interfered with the
Dollé and coworkers synthesized an octasaccharide heparin mimetic that interfered with the
process of angiogenesis and metastasis [102]. It potently inhibited heparanase, FGF2, VEGF, SDF-1α,
process of angiogenesis and metastasis [102]. It potently inhibited heparanase, FGF2, VEGF, SDF-1α,
PDGF-β, and cell proliferation in vitro and is being tested in vivo in animal models.
PDGF-β, and cell proliferation in vitro and is being tested in vivo in animal models.
4.1.2. Non-Saccharide GAG Mimetics
4.1.2. Non-Saccharide GAG Mimetics
A library of small HS mimetics was developed by Parish and co-workers from sulfation
A library of small HS mimetics was developed by Parish and co-workers from sulfation of
of cyclitols [103]. They screened the library of 15 molecules against a panel of GAG binding
cyclitols [103]. They screened the library of 15 molecules against a panel of GAG binding proteins
proteins and observed a clear relationship between the structure and the protein they recognized.
and observed a clear relationship between the structure and the protein they recognized. They found
They found that Compound a (Figure 4A) with an ethyl linker was a potent inhibitor of FGF-1,
that Compound a (Figure 4A) with an ethyl linker was a potent inhibitor of FGF-1, and Compound
and Compound b (Figure 4A) with an octyl linker was a potent inhibitor of FGF-2 and VEGF, but not
b (Figure 4A) with an octyl linker was a potent inhibitor of FGF-2 and VEGF, but not FGF-1. These
FGF-1. These compounds, because of their ability to inhibit different growth factors, are expected to
compounds, because of their ability to inhibit different growth factors, are expected to possess
possess antitumor activity.
antitumor activity.
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Figure
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of non-saccharide
glycosaminoglycan
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Figure
4. Chemical
structures
of non-saccharide
glycosaminoglycan
mimetics
developed
as anti-cancer
anti-cancer
agents:
(A)
sulfated
cyclitols
inhibiting
growth
factors,
(B)
angiogenesis
inhibitors,
agents: (A) sulfated cyclitols inhibiting growth factors, (B) angiogenesis inhibitors, (C) G2.2, a CSC
(C) G2.2,
CSC
inhibitor,
and (D) {Z}12, a metastasis inhibitor.
inhibitor,
and a(D)
{Z}
12 , a metastasis inhibitor.

co-workers
reportedthe
thedevelopment
development of
that
inhibit
angiogenesis
[104].[104].
DesaiDesai
and and
co-workers
reported
ofHS
HSmimetics
mimetics
that
inhibit
angiogenesis
By
screening
a
library
of
18
sulfated-small
molecules
belonging
to
different
chemical
classes
(flavone,
By screening a library of 18 sulfated-small molecules belonging to different chemical classes (flavone,
flavan, chalcone, stilbene, styrene, and isoquinoline scaffolds), they identified potent molecules
flavan, chalcone, stilbene, styrene, and isoquinoline scaffolds), they identified potent molecules
(Figure 4B) that inhibited the formation of angiogenesis at a 100 µM concentration.
(Figure 4B)
that inhibited the formation of angiogenesis at a 100 µM concentration.
They also reported the development of a small molecule GAG mimetic selectively targeting
They
also
development
of dual-screen
a small molecule
mimetic
selectively
targeting
colon CSCs reported
[105]. Theythe
developed
a tandem,
strategy GAG
to screen
selectively
for molecules
colontargeting
CSCs [105].
They
developed
a
tandem,
dual-screen
strategy
to
screen
selectively
for
molecules
CSCs over the population of bulk cancer cells. Using this screening protocol and molecular
targeting
CSCs over algorithm,
the population
of bulkthat
cancer
Using
screening
and
molecular
dynamics-based
they showed
G2.2cells.
(Figure
4C) isthis
a structural
andprotocol
functional
mimetic
of HS06. G2.2algorithm,
inhibited the
growth
of CSCs
from (Figure
multiple 4C)
cell is
lines
by induction
apoptosis and
dynamics-based
they
showed
that G2.2
a structural
andoffunctional
mimetic
inhibition
of
self-renewal
factors.
G2.2
also
inhibited
the
growth
of
tumor
in
CSC
induced
xenografts
of HS06. G2.2 inhibited the growth of CSCs from multiple cell lines by induction of apoptosis and
in vivo
inhibition
of[106].
self-renewal factors. G2.2 also inhibited the growth of tumor in CSC induced xenografts
Another recent study highlighted the use of polyproline-based GAG mimetics (PGMs) that
in vivo [106].
recapitulate key structural features of GAGs, including periodicity, the length of repeating units,
Another recent study highlighted the use of polyproline-based GAG mimetics (PGMs) that
recapitulate key structural features of GAGs, including periodicity, the length of repeating units,
turnability, and helicity, as shown through molecular dynamics simulations [107]. One of the synthesized
PGMs, {Z}12 (Figure 4D), inhibited the interaction of CS-E with P-selectin, which is implicated in
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turnability, and helicity, as shown through molecular dynamics simulations [107]. One of the
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synthesized PGMs, {Z}12 (Figure 4D), inhibited the interaction of CS-E with P-selectin, which is
implicated in metastasis and inflammation. It also reduced metastasis in vivo as effectively as heparin
and tinzaparin.
Additionally,
{Z}12reduced
did not
have inhibitory
on as
theheparin
coagulation
cascade
metastasis
and inflammation.
It also
metastasis
in vivo aseffects
effectively
and tinzaparin.
enzymes, resulting
in no/minimal
bleedingeffects
side-effects.
animal models,
it did
not induce
weight
Additionally,
{Z}12 did
not have inhibitory
on theIn
coagulation
cascade
enzymes,
resulting
in
loss,
elevate
liver
damage
markers,
or
cause
histopathological
abnormalities,
suggesting
its
safe
use
no/minimal bleeding side-effects. In animal models, it did not induce weight loss, elevate liver damage
in vivo. or cause histopathological abnormalities, suggesting its safe use in vivo.
markers,
Int. J. Mol. Sci. 2019, 20, 1963

4.2. GAG Mimetics as Anti-Inflammatory Agents
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Mimetics
4.2.1. Saccharide-Based
GlycoMimetics
Inc. has
has developed
developed aa pan-selectin
pan-selectin antagonist,
antagonist, GMI-1070
GMI-1070 (Figure
(Figure 5A),
5A), to
to treat
GlycoMimetics Inc.
treat
vascular
occlusions
in
people
with
sickle
cell
disease
[108].
Recurrent
vascular
occlusions,
as
seen
vascular occlusions in people with sickle cell disease [108]. Recurrent vascular occlusions, as seen in
in
sickle
lead
to chronic
inflammation
and, eventually,
irreversible
organ damage.
sickle cell
celldisease,
disease,
lead
to chronic
inflammation
and, eventually,
irreversible
organGMI-1070,
damage.
when
administered
in mice, resulted
in resulted
an increase
in increase
leukocyte
which
is indicative
selectin
GMI-1070,
when administered
in mice,
in an
inrolling,
leukocyte
rolling,
which is of
indicative
inhibition.
It
reduced
leukocyte
adherence
to
endothelium,
inhibited
red
blood
cell
and
leukocyte
of selectin inhibition. It reduced leukocyte adherence to endothelium, inhibited red blood cell and
interactions,
and also inhibited
vascular
occlusion.
was demonstrated
to be safe in Phase
leukocyte interactions,
and also
inhibited
vascularIt occlusion.
It was demonstrated
to beI clinical
safe in
trials
reduced
timereduced
to resolve
events inocclusive
Phase II [110],
is currently
in
Phase[109],
I clinical
trialsthe
[109],
thevascular
time to occlusive
resolve vascular
eventsand
in Phase
II [110],
Phase
III
clinical
trials.
and is currently in Phase III clinical trials.

Figure 5. Chemical structures of saccharide glycosaminoglycan mimetics developed as anti-inflammatory
agents: (A) GMI-1070, (B) 2,4-O-di-sulfated iduronic acid (Di-S-IdoA), (C) Hep- super-sulfated
disaccharide (SSD), and (D) KanCbz and NeoCbz.
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the inflammatory
response. into the lungs, indicating a potential use of the compound to
areduce
reduction
in leukocyte recruitment
Another
study showed
the development of a super-sulfated disaccharide sequence of heparin
reduce
the inflammatory
response.
(Hep-SSD;
Figure
fromthe
a non-anticoagulant
inactive disaccharide
[112].sequence
Hep-SSDofinhibited
Another
study5C)
showed
development of a super-sulfated
disaccharide
heparin
allergic
airway
responses
in
a
sheep
model
of
allergic
asthma
when
given
by
both
aerosol
and
oral
(Hep-SSD; Figure 5C) from a non-anticoagulant inactive disaccharide [112]. Hep-SSD inhibited allergic
administration
routes
in a dose-dependent
manner.when given by both aerosol and oral administration
airway
responses
in a sheep
model of allergic asthma
Kerns
and co-workersmanner.
screened a panel of N-arylacyl-O-sulfated aminoglucosides against
routes
in a dose-dependent
neutrophil
proteases, screened
including ahuman
elastase, proteinase
3, and cathepsin
G,
Kerns serine
and co-workers
panel neutrophil
of N-arylacyl-O-sulfated
aminoglucosides
against
which are upregulated
in inflammatory
lung neutrophil
conditions elastase,
such as chronic
obstructive
pulmonary
neutrophil
serine proteases,
including human
proteinase
3, and cathepsin
G,
disease,are
cystic
fibrosis, and
acute lung injury
[113].
They identified
lead compounds
5D),
which
upregulated
in inflammatory
lung
conditions
such astwo
chronic
obstructive (Figure
pulmonary
a kanamycin-based
compound
a neomycin-based
compound
(NeoCbz),
as potent
disease,
cystic fibrosis,
and acute (KanCbz)
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[113].
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(Figure
5D),
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of the proteases.
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that these (NeoCbz),
lead compounds
can
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(KanCbz) The
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inhibitor
drugs
for
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inflammation
mediated
inhibitors of one or more of the proteases. The results demonstrated that these lead compounds can be
by proteases.
further
exploited for multi-target inhibitor drugs for attenuating inflammation mediated by proteases.
®s (ReGeneraTing Agents; Figure 6) are
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RGTA
s (ReGeneraTing
another class of HS mimetics that are designed to
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[114].
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their structure
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they are
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and they areconditions,
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forskin
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Figure 6. Chemical structure of RGTA®®.
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The ability of sulfated low molecular weight lignins to inhibit inflammation caused by human
The ability
of sulfated
low
molecular
lignins to
inhibit
inflammation
by human
neutrophil
elastase,
for the
treatment
ofweight
emphysema,
was
studied
by Desai caused
and co-workers.
neutrophil
for thecaffeic
treatment
emphysema,
was studied by Desai and co-workers. They
They
foundelastase,
that sulfated
acid of
(CDSO
3 ; Figure 7) inhibited human neutrophil elastase in
found
that
sulfated
caffeic
acid
(CDSO
3; Figure 7) inhibited human neutrophil elastase in a
a concentration-dependent manner with an IC50 of 0.43 ± 0.04 µM and showed anti-oxidative and
concentration-dependent
manner
anFurthermore,
IC50 of 0.43 it± attenuated
0.04 µM and
showed anti-oxidative
and
anti-inflammatory
properties
in vitrowith
[115].
the development
of emphysema
anti-inflammatory
properties
in
vitro
[115].
Furthermore,
it
attenuated
the
development
of
in rat models where emphysema was induced with human neutrophil elastase and cigarette smoke
emphysema
in
rat
models
where
emphysema
was
induced
with
human
neutrophil
elastase
and
extract [116]. It was able to reduce inflammation in both a preventive and interventional manner when
cigarette smoke
extract
It was
able
to reduce
inflammation
in both a preventive and
administered
locally
to the[116].
lung with
doses
as low
as 30–100
µg/kg.
interventional
manner
when
administered
locally
to
the
lung
with
doses
as low
30–100
µg/kg.
When endothelial lung cell death was induced in vitro using inhibitors
for as
histone
deacetylase
and VEGF receptor, or through cigarette smoke, CDSO3 treatment significantly inhibited cell death
when compared to control [117]. In a rat model with induced apoptotic emphysema, 60 µg/kg of
CDSO3 produced significant blockade of lung damage and resulted in increased exercise endurance.
Overall, CDSO3 appears to be promising in developing a novel treatment for emphysema.
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5. Conclusions
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glycans lagged far behind other macromolecules because of limited technology available to study their
5. Conclusions
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arrays,
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to
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expanding
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RNA, and proteins, and sugars were considered as a mere source of energy, lacking any other
Today,activities.
glycans are
known
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roles was
in anfocused
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GAGs, in particular,
regulate
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Hence,
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of research
on understanding
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DNA,
aRNA,
multitude
of functions
interacting
with proteins,
and tissues
in the human
body. They
play
and proteins
play by
in different
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andcells,
pathological
conditions.
Furthermore,
studies
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role
in
almost
every
physiological
activity
in
the
body
and
are
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in
maintaining
glycans lagged far behind other macromolecules because of limited technology available to study
homeostasis.
Moreover,
in their expression
and/or the structure
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their structural
diversitychanges
and complexity.
With advancements
in mass of
spectrometry,
lectin and
multiple
pathological
conditions
and
are
being
employed
as
biomarkers
for
disease
progression.
antibody arrays, imaging technologies, glycan microarrays, and bioinformatic tools, it has now
Since
the discovery
than 100
yearsofago,
GAGs have been widely studied
become
possible
to study of
theheparin,
glycome,more
expanding
the field
glycobiology.
as therapeutics
for cancer,
inflammation,
infections,
diseases, etc.
However,
their success
Today, glycans
are known
to play diverse
roles inlung
an organism.
GAGs,
in particular,
regulateisa
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of
their
inherent
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and
affinity
towards
multiple
targets,
leading
multitude of functions by interacting with proteins, cells, and tissues in the human body. They
play
to
side-effects.
a result
of dealing
with the
limitations
GAGs,
to be
a drift from
a major
role inAs
almost
every
physiological
activity
in theofbody
andthere
are seems
essential
in maintaining
heterogeneous
GAGs derived
frominanimal
sources to homogenous,
synthetic,
semi-synthetic
GAG
homeostasis. Moreover,
changes
their expression
and/or the structure
of or
GAGs
are observed
in
mimetics.
These
GAG
mimetics
not
only
offer
advantages
with
homogeneity
and
synthetic
feasibility,
multiple pathological conditions and are being employed as biomarkers for disease progression.
but also
(usually)
possessof
increased
selectivity,
and
better
pharmacokinetic
properties
with
Since
the discovery
heparin,potency,
more than
100 years
ago,
GAGs
have been widely
studied
as
lesser
adverse
effects.
In
conclusion,
the
field
of
glycosaminoglycan
drug
discovery
is
rapidly
therapeutics for cancer, inflammation, infections, lung diseases, etc. However, their success is being
progressing
withofmultiple
GAGs/GAG
mimetics already
in the towards
clinic. The
next decade
is going
to see
halted because
their inherent
heterogeneity
and affinity
multiple
targets,
leading
to
major
changes
in
both
the
structural
studies
of
GAGs
and
their
corresponding
role
in
therapy
with
side-effects. As a result of dealing with the limitations of GAGs, there seems to be a drift from
more
GAG-based
drugs
making
their
way to
the clinic
and rewritingsynthetic,
the historical
notion of GAGs
in
heterogeneous
GAGs
derived
from
animal
sources
to homogenous,
or semi-synthetic
GAG
drug
discovery.
mimetics.
These GAG mimetics not only offer advantages with homogeneity and synthetic feasibility,

but also (usually) possess increased potency, selectivity, and better pharmacokinetic properties with
lesser adverse effects. In conclusion, the field of glycosaminoglycan drug discovery is rapidly
Conflicts of Interest: The author declares no conflict of interest.
progressing with multiple GAGs/GAG mimetics already in the clinic. The next decade is going to see
major changes in both the structural studies of GAGs and their corresponding role in therapy with
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